Scan to get started on Sahi
Rethink Trading
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ | 38K+ Ratings | IFTA Startup of the year 2025 | 8M+ downloads
Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.
Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.
Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks
Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.
Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.
High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news
MPS Limited Approves Unaudited Financial Results for Q2 FY27
MPS Limited convened its board meeting on November 3, 2026, to consider unaudited financial results for Q2 FY27. The company reported Q2 revenue of ₹2.24 billion versus ₹1.94 billion YoY (as stated in the source alert; not independently verified). Historical filings confirm strong financial foundations with FY26 EBITDA standing at ₹236 crore.
Ion Exchange Reports Q2 Revenue of ₹6.74 Billion Down From ₹7.34 Billion YoY
Ion Exchange (India) reported a year-on-year revenue drop to ₹6.74 billion for Q2, down from ₹7.34 billion in Q2 of the previous fiscal year. The decline reflects top-line compression in quarter-on-quarter operating performance.
Aarti Drugs Reports Q2 Revenue Of ₹706 Crore Versus ₹580 Crore YoY
Aarti Drugs recorded Q2 revenue of ₹706 crore, up 21.72% YoY (derived: ₹706 crore vs ₹580 crore) from ₹580 crore in the prior-year period. The operational performance comes following an executive leadership transition that took effect on October 1, 2026.
